Fifty One Capital updated report, page-20

i thought fifty one did a good job of explaining the expected upcoming results....

all clinical trials patients:

- will have a stronger dose of the drug compared to the real life TGA patients,
- have the longer time frame of dosage, being 6 weeks

the 6 weeks seems to be fairly significant, having had the majority of one batch of 25 patients undergo 6 weeks, which had a 60% result of patients experiencing pain reduction...as opposed to the average of 50% to date....with a lot of those patients having shorter treatment than 6 weeks, being estimated at mostly 3-4 weeks..... it really is hard to expect anything other than improvement from the clinical trials... of course, nothing is a given...